CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Recruiting
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
11/29/2023
Locations: Research Solutions of Arizona, Litchfield Park, Arizona +3 locations
Conditions: Hereditary Angioedema (HAE)